Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: Competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes

Xenobiotica

Volumn 42, Issue 5, 2012, Pages 483-495

  Choi, Young H ^a   Lee, Myung G ^b  

^a Dongguk University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

competitive inhibition; CYP; drug interaction; metformin; Nifedipine; rats

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; ISOENZYME; ITRACONAZOLE; METFORMIN; NIFEDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; HYPERTENSION; INTESTINE; LIVER; MALE; METABOLIC INHIBITION; MICHAELIS CONSTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; VELOCITY;

ADMINISTRATION, ORAL; ANIMALS; BACULOVIRIDAE; BLOOD PROTEINS; CELL LINE; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG INTERACTIONS; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; ISOENZYMES; KINETICS; MALE; METFORMIN; MICROSOMES, LIVER; NIFEDIPINE; PROTEIN BINDING; QUININE; RATS; RATS, SPRAGUE-DAWLEY; SULFAPHENAZOLE; TROLEANDOMYCIN;

RATTUS;

EID: 84859343134     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.633177     Document Type: Article

References (39)

1. Abou-Auda HS, Najjar TA, Al-Khamis KI, Al-Hadiya BM, Ghilzai NM, Al-Fawzan NF. (2000). Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. J Pharm Biomed Anal 22:241-249. (Pubitemid 30109343)
2. Arlotto MP, Sonderfan AJ, Klaassen CD, Parkinson A. (1987). Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase. Biochem Pharmacol 36:3859-3866. (Pubitemid 18010945)
3. Baker M, Parton T. (2007). Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica 37:1110-1134. (Pubitemid 350035537)
4. Bachmann KA, Lewis JD. (2005). Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072. (Pubitemid 40695974)
5. Beckman JA, Creager MA, Libby P. (2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287:2570-2581. (Pubitemid 34517204)
6. Boudinot FD, Jusko WJ. (1984). Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774-780.
7. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Cao QR, Kim TW, Choi JS, Lee BJ. (2005). Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats. Biopharm Drug Dispos 26:427-437. (Pubitemid 43115919)
9. Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
10. Choi YH, Lee MG. (2006). Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: Involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol 149:424-430. (Pubitemid 44582249)
11. Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543-2552. (Pubitemid 44726394)
12. Choi YH, Chung SJ, Lee MG. (2008). Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: Competitive inhibition of metabolism via hepatic CYP3A1/2. Br J Pharmacol 153:1568-1578. (Pubitemid 351481509)
13. Choi YH, Lee U, Lee BK, Lee MG. (2010). Pharmacokinetic interaction between itraconazole and metformin in rats: Competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 161:815-829.
14. Correia MA. (1995). Appendix B. Rat and human liver cytochrome P450. Substrate and inhibitor specificities and functional markers, second ed. in: Oritz de Montellano P.R. (Ed.) Cytochrome P450. Structure, Mechanism, and Biochemistry, New York and London: Plenum Press, 607-630.
15. Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. (2004). Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: A 12-month, randomized, double-blind study. Clin Ther 26:1228-1236. (Pubitemid 39445345)
16. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61-90.
17. Gibaldi M, Perrier D. (1982). Pharmacokinetics, 2nd edn. New York: Marcel-Dekker.
18. Grundy JS, Eliot LA, Foster RT. (1997). Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18:509-522. (Pubitemid 27338982)
19. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060. (Pubitemid 17204301)
20. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. (2002). Transfer of metformin into human milk. Diabetologia 45:1509-1514. (Pubitemid 35352043)
21. Jassim KA, Sequeira RP, Damanhori AHH. (2005). Evaluation of drug therapy and risk factors in diabetic hypertensives: A study of the quality of care provided in diabetic clinics in Bahrain. J Eva Clin Prac 11:121-131. (Pubitemid 40432587)
22. Kaminsky LS, Zhang QY. (2003). The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525. (Pubitemid 37466920)
23. Kobayashi K, Urashima K, Shimada N, Chiba K. (2003). Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833-836. (Pubitemid 36759051)
24. Kondo S, Sugimoto I. (1987). Moment analysis of intravenous, intraduodenal, buccal, rectal and percutaneous nifedipine in rats. J Pharmacobio-dyn 10:462-469. (Pubitemid 18051510)
25. Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640. (Pubitemid 14070321)
26. Lineweaver H, Burk D. (1934). The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
27. Martignoni M, Groothuis G, de Kanter R. (2006). Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34:1047-1054. (Pubitemid 43763764)
28. Ogiso T, Iwaki M, Tanaka H, Kobayashi E, Tanino T, Sawada A, Uno S. (1999). Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Biol Pharm Bull 2:196-199.
29. Oie S, Guentert TW. (1982). Stability of heparin and other fractions of glycosaminoglycan sulfates in human digestive juices. J Pharm Sci 71:127-128.
30. Parving HH. (2002). Controlling hypertension in diabetes. Acta Diabetol 39 Suppl 2:S35-S40.
31. Ross PH, Ciosk BG, Kallweit D, Kauczinski D, Hanstein WG. (1993). Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem Pharmacol 45:2239-2250. (Pubitemid 23171085)
32. Scheen AJ. (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359-371.
33. Segel I. (1975). Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme system. Wiley: New York. 100-206.
34. Setter SM, Iltz JL, Thams J, Campbell RK. (2003). Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin Ther 25:2991-3026. (Pubitemid 38096142)
35. Sinclair JF, Szakacs JG, Wood SG, Kostrubsky VE, Jeffery EH, Wrighton SA, Bement WJ, Wright D, Sinclair PR. (2000). Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: Protection by triacetyloleandomycin. Biochem Pharmacol 59:445-454. (Pubitemid 30015975)
36. Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM. (1997). Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382. (Pubitemid 27166736)
37. Wilkinson GR, Shand DG. (1975). Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
38. Yang KH, Jung YS, Lee DY, Lee JH, Kim YC, Lee MG. (2008). Time-dependent effects of Klebsiella pneumoniae endotoxin (KPLPS) on the pharmacokinetics of theophylline in rats: Return of the parameters in 96-hour KPLPS rats to the control levels. Drug Metab Dispos 36:811-815. (Pubitemid 351574899)
39. Yoshioka M, Ohnishi N, Sone N, Egami S, Takara K, Yokoyama T, Kuroda K. (2004). Studies on interactions between functional foods or dietary supplements and medicines. III. Effects of ginkgo biloba leaf extract on the pharmacokinetics of nifedipine in rats. Biol Pharm Bull 27:2042-2045. (Pubitemid 41701588)